Each of the pathological stages (I-IIIa) of surgically resected non-small-cell lung cancer has hidden biological heterogeneity, manifested as heterogeneous outcomes within each stage. Thus, the finding of robust and precise molecular classifiers with which to assess individual patient risk is an unmet medical need. Here, we identified and validated the clinical utility of a new prognostic signature based on three proteins (BRCA1, QKI, and SLC2A1) to stratify early-stage lung adenocarcinoma patients according to their risk of recurrence or death. Patients were staged according to the new International Association for the Study of Lung Cancer (IASLC) staging criteria (8th edition, 2018). A test cohort (n = 239) was used to assess the value of this new prognostic index (PI) based on the three proteins. The prognostic signature was developed by Cox regression with the use of stringent statistical criteria (TRIPOD: Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis). The model resulted in a highly significant predictor of 5-year outcome for disease-free survival (p < 0.001) and overall survival (p < 0.001). The prognostic ability of the model was externally validated in an independent multi-institutional cohort of patients (n = 114, p = 0.021). We also demonstrated that this molecular classifier adds relevant information to the gold standard TNM-based pathological staging, with a highly significant improvement of the likelihood ratio. We subsequently developed a combined PI including both the molecular and the pathological data that improved the risk stratification in both cohorts (p ≤ 0.001). Moreover, the signature may help to select stage I-IIA patients who might benefit from adjuvant chemotherapy. In summary, this protein-based signature accurately identifies those patients with a high risk of recurrence and death, and adds further prognostic information to the TNM-based clinical staging, even when the new IASLC 8th edition staging criteria are applied. More importantly, it may be a valuable tool for selecting patients for adjuvant therapy.
Introduction
Lung cancer is the leading cause of cancer-related death worldwide [1] . Usually, two of three lung cancer patients are diagnosed at an advanced stage of the disease, when the curative options and survival rates are poor. Even among early-stage patients, the mortality risk remains high, with relapse rates of 30-45% within 5 years of diagnosis [2] . According to results from randomized clinical trials, adjuvant chemotherapy is recommended for stage II-III patients. However, the indication of chemotherapy for stage I patients is still a matter of debate [3] . Early identification of patients with a high risk of recurrence after surgery is crucial for the design of tailored management strategies to reduce lung cancer mortality. Moreover, lung cancer screening by low-dose computed tomography has been introduced into routine clinical practice, and is being entered into reimbursement schemes [4] to reduce lung cancer mortality [5] . The implementation of lung cancer screening will increase the number of surgically amenable lung cancer patients diagnosed in early stages within the next few years.
The tumour-node-metastasis (TNM) staging system is the current gold standard for estimating prognosis in non-small-cell lung cancer (NSCLC) patients. However, it is not sufficient for accurate survival prediction, as heterogeneous clinical outcomes with identical TNM staging are commonly observed. Despite the efforts over the last decade, to date none of the many proposed biological features has been incorporated into routine clinical practice [6, 7] . In recent years, attention has shifted to high-throughput genomic tools; in particular, microarray technology has been used to identify prognostic RNA-based profiles in NSCLC. More recently several polymerase chain reaction (PCR)-based signatures have been developed and validated to define the risk of death, although they have not yet been prospectively validated [8] [9] [10] [11] . It is of note that the need for good-quality RNA samples may limit the outcome of these signatures in routine daily practice. Alternatively, the identification and quantification of protein expression in tissue sections is a very well-mastered technique that is available in every hospital. Specifically, immunohistochemistry (IHC) has been used as an approved companion biomarker for several novel therapeutic strategies [12, 13] .
In the present study, we developed and validated a new molecular prognostic signature for lung adenocarcinoma (ADC). Specifically, we use immunodetection-based techniques to assess the expression of three prognostic proteins in our cohorts of patients. Using this signature, we were able to identify a subset of stage I-II patients with a higher risk of recurrence and survival who may be in need of more aggressive therapy or closer follow-up. We clearly show that our classifier offers additional information to that provided by the TNM staging system. More importantly, our model gives insights into which patients may benefit from adjuvant therapy.
Materials and methods

Patients
Primary ADC tumour samples were collected from consecutive population cohorts from the University of Texas MD Anderson Cancer Center (Houston, TX, USA) (MDA), the CIBERES multi-institutional Pulmonary Biobank Platform (Spain) [14] , and Clínica Universidad de Navarra (Pamplona, Spain) (CUN). The MDA cohort was composed of 239 ADC patients diagnosed from 1999 to 2008 at the MDA. A second cohort of 114 ADC patients was also analysed. These lung ADC patients were diagnosed from 2000 to 2013. Inclusion criteria were as follows: patients with lung ADC, complete resection of the primary tumour, absence of cancer within the previous 5 years, and absence of chemotherapy or radiotherapy treatment prior to surgery. Tumours were classified according to the World Health Organization 2004 classification [15] , and the 8th TNM edition was used for tumour stratification [16] . Tissue microarrays were constructed by obtaining three cores from each tumour at three different areas with a manual tissue arrayer. REMARK guidelines were strictly followed throughout the study [17] . For survival analysis, the follow-up period was restricted to 60 months in all cohorts. Disease-free survival (DFS) and overall survival (OS) were defined as the time from the date of surgery to the date of recurrence or death, respectively. The study was conducted according to the Declaration of Helsinki, and was approved by the Institutional Review Board and Ethical committee of the MDA, CUN, and CIBERES. Written informed consent was obtained from each patient. The characteristics of the cohorts are shown in supplementary material, Table S1 .
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Microorganisms and Cell Cultures (Braunschweig, Germany). All of the cell lines were grown in RPMI medium with 2 mM L-glutamine, 10% Fetalclone (Thermo Fisher Scientific, Waltham, MA, USA), 100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen, Barcelona, Spain). Cell lines were authenticated by analysis of their genetic alterations.
Antibody specificity validation
Specificities of the antibodies were assessed with western blotting (WB), IHC and small interfering RNA (siRNA) knockdown technology in NSCLC cells. Nuclear and cytoplasmic protein fractions of different cell lines were isolated, and formalin-fixed paraffin-embedded (FFPE) blocks of the same cells were prepared. For each antibody, the appearance of only specific molecular weight bands of the expected size in the western blot was confirmed. In most cases, one band corresponding to the canonical isoform appeared. When two or more bands were detected, we checked whether they corresponded to gene splice isoforms. Antibodies recognizing non-specific bands were discarded. Also, the expression of the protein was studied by IHC in the cell line FFPE blocks, and the correlation of expression detected by WB and expression detected by IHC was analysed. Additionally, the correct localization in the subcellular compartment was checked with both methods. In cases of inconclusive results, antibody specificity was evaluated by siRNA knockdown. A flowchart including the steps followed at this point is shown in Figure 1 .
Immunohistochemistry
Immunohistochemical staining for BRCA1 (GTX70113; Genetex, Irvine, CA, USA), CDC6 (sc-56273; Santa Cruz Biotechnology, Dallas, TX, USA), LIG1 (Areta International, Gerenzano, VA, Italy), QKI (HPA019123; Sigma-Aldrich, Madrid, Spain), RAD51 (PC130; Calbiochem, San Diego, CA, USA), RAE1 (EPR6923; Genetex, Irvine, CA, USA), RRM2 (WH0006241M1; Sigma-Aldrich, Madrid, Spain), SIRT2 (sc-28298; Santa Cruz Biotechnology, Dallas, TX, USA), SLC2A1 (21829-1-AP; Proteintech, Chicago, IL, USA), SNRPE (20407-1-AP; Proteintech, Rosemont, IL, USA), SRSF1 (32-4600; Zymed, San Francisco, CA, USA) and STC1 (sc-14346; Santa Cruz Biotechnology, Dallas, TX, USA) was performed on sections of FFPE tissues and cell blocks. After dewaxing, sections were hydrated through a graded series of ethanol. Endogenous peroxidase activity was quenched with 3% H 2 O 2 for 10 min. Heat-mediated antigen retrieval was conducted in a Lab Vision PT module at 95 ∘ C for 20 min, either with citrate buffer (pH 6) (Thermo Fisher Scientific) or Tris-EDTA (pH 9) (Thermo Fisher Scientific), as indicated. Sections were incubated with primary antibodies diluted in a special buffer (antibody diluent; Dako, Glostrup, Denmark) overnight at 4 ∘ C in a humidity chamber. After being rinsed with Tris-buffered saline, Flowchart showing the main steps of the study. We first selected a source of genes that had been previously related to lung cancer prognosis. We analysed the prognostic value at the mRNA level for each gene individually. After validation of commercial antibodies, we carefully chose those genes with specific antibodies that met the above requirements. We studied the expression of 12 selected proteins and developed the prognostic model by Cox regression in the training cohort (MDA cohort 
Evaluation of immunostaining
Tumours were evaluated by two experienced observers (E.M.T. and M.J.P.). The expression of the proteins was scored as the percentage of positive cells (0-100%), and the intensity of staining (1, weak; 2, moderate; and 3, strong). The final H-score was calculated as the sum of the product of staining intensity (0-3) by extension (0-100) at each intensity level as previously described [27] . Staining in different subcellular compartments (nuclear, cytoplasmic, and membranous) was evaluated independently for each marker. The agreement between the two observers was verified by the use of Gwet's AC1. Discordant independent readings were resolved by simultaneous review by the two observers.
Western blotting
Proteins were denatured in sodium dodecyl sulphate (SDS) sample buffer (Bio-Rad Laboratories, Hercules, CA, USA) at 95 ∘ C for 5 min, separated by SDS polyacrylamide gel electrophoresis on NuPAGE Novex 10%, 12% or 4-12% Bis-Tris gels (Invitrogen) in MOPS or MES buffer, and transferred to nitrocellulose membranes (pore size, 0.45 μm; Bio-Rad). Membranes were blocked in 5% non-fat milk for 1 h, and incubated overnight at 4 ∘ C with the primary antibodies at 1:500 for anti-SIRT2 and anti-SNRPE, 1:1000 for anti-BRCA1, anti-SLC2A1, anti-RRM2, anti-CDC6, anti-RAE1, and anti-STC1, 1:2000 for anti-QKI and anti-LIG1, 1:4000 for anti-β-actin, 1:5000 for anti-lamin A/C, 1:8000 for anti RAD51, and 1:10 000 for anti-glyceraldehyde-3-phosphate dehydrogenase and anti-SRSF1. Secondary antibodies (anti-rabbit IgG NA934 or anti-mouse IgG NA931; 1:2000; GE Healthcare, Little Chalfont, Buckinghamshire, UK) were applied for 1 h at room temperature, and chemiluminescence detection was performed with Lumi-Light PLUS (Roche, Manhein, Germany).
Statistical analysis
TRIPOD criteria were followed in our study [28] , and statistical analyses were performed with SPSS 22.0 (IBM, Armonk, NY, USA) and STATA/IC 12.1 (StataCorp, College Station, TX, USA). Generation of the prognostic signatures was performed in the MDA cohort with regression Cox analysis [29] . The discriminative ability of the prognostic index (PI) was assessed by the use of Harrell's concordance coefficient (C-index) and the log rank test for the PI dichotomized at the median [30] . The prognostic model was internally validated to quantify any optimism regarding the predictive performance through a shrinkage penalization strategy [31] . Univariate and multivariate Cox proportional hazards analyses including clinical and pathological variables were used to assess the prognostic role of the molecular model (PI). Only variables with p < 0.25 in the univariate analysis were included in the multivariate analysis. The external validation of the prognostic models was performed in the second cohort (CIBERES-CUN). We calculated the C-index and the survival curves with the Kaplan-Meier method. Survival curves were compared by use of the log rank test as previously described. The clinical utility of the model was tested by comparing the likelihood ratio of the stage alone with that after the addition of the molecular model (PI) by use of a bivariable Cox analysis in the MDA cohort. The combined prognostic index (CPI) was also developed by Cox regression. Also, the discriminative ability of the CPI was assessed as described above (C-index and the log rank test for the CPI dichotomized at the median). Statistical methods are detailed in supplementary material, Supplementary materials and methods.
Results
Gene selection to develop the prognostic signature
With the aim of generating a protein-based signature to predict disease outcome, we first identified in the literature genes whose expression was associated with clinical outcome. A flowchart with all the steps followed in this study is shown in Figure 1 . We selected those genes that were significantly associated with prognosis in at least two previously published gene expression signatures (20 genes of 967). Moreover, on the basis of our previous publications, nine additional biomarkers were added to the list. In the next step of the gene-selection process, we conducted an in silico survival analysis to validate the prognostic value of these genes at the RNA level by the use of different NSCLC databases. Twenty-one genes showing prognostic value in at least two databases were selected (supplementary material, Table S3 ). Subsequently, those genes (n = 5) that lacked reliable commercial antibodies in the antibodypedia database (www .antibodypedia.com) were discarded. In the last step, the antibody specificity for the 16 remaining genes was evaluated by IHC, WB and siRNA technology (supplementary material, Figures S1-S12). Finally, we selected 12 cancer-related genes (BRCA1, CDC6, LIG1, QKI, RAD51, RAE1, RRM2, SIRT2, SLC2A1, SNRPE, SRSF1, and STC1) for which specific antibodies met our requirements, and developed the prognostic model. The strategy used for gene selection is described in more detail in supplementary material, Supplementary materials and methods and Table S4 . Development of a protein-based signature for risk stratification in lung ADC First, we analysed the expression of the 12 selected proteins by IHC in patients from the MDA cohort. We studied each subcellular localization (nuclear, cytoplasmic, and membranous) as independent variables (supplementary material, Table S5 ). Figure 2 shows representative images of the immunostained tumours. Next, we performed Cox regression analysis to generate 20 statistically significant prognostic models. We calculated the PI for each patient, and then the C-index to evaluate the quality of each model. Finally, the best model was selected as the model that yielded a high C-index and high parsimony. The group with predicted low risk had significantly longer DFS (p = 0.004) and OS (p < 0.001) than the high-risk group in the training cohort ( Figure 3A) . Univariate Cox regression analysis showed that the molecular PI was significantly associated with both DFS [p < 0.001, hazard ratio (HR) = 2.89, 95% confidence interval (CI) 1.82-4.57] and OS (p < 0.001, HR = 3.95, 95% CI 2.32-6.72). As expected, the prognostic significant of stage was very high for both DFS (p < 0.001) and OS (p = 0.001). After a multivariate adjustment (stage, gender, and adjuvant treatment), the molecular PI remained a significant predictor of 5-year outcome: p < 0.001, HR = 2.56, 95% CI 1.56-4.20 for DFS; and p < 0.001, HR = 3.69, 95% CI 2.10-6.50 for OS. All the results from the Cox proportional hazards analysis are summarized in Table 1 .
Usefulness of the three-protein prognostic signature to stratify risk in early-stage lung ADC patients
In order to evaluate the potential utility of the PI for estimation of prognosis in early-stage lung ADC, we conducted a specific analysis of our signature on samples from stage I-II patients (n = 187) of the MDA series (n = 239). Kaplan-Meier survival curves and log rank tests showed statistical differences between the two groups in both DFS (p = 0.030) and OS (p = 0.003) ( Figure 3B ).
We next tested the independent prognostic ability of the PI in relation to other parameters with prognostic value in this subgroup of patients. The molecular PI remained an independent risk factor, after adjustment for stage, for both DFS (p = 0.024, HR = 1.99, 95% CI 1.10-3.62) and OS (p = 0.007, HR = 2.54, 95% CI 1.29-5.01). The results of the univariate and multivariate Cox proportional hazards analysis are summarized in Table 2 .
Validation of the protein-based prognostic score
We performed a further analysis to validate this promising prognostic model in an independent set of lung ADC patients (CIBERES-CUN cohort; supplementary material, Table S1 ). We used IHC to analyse 99 stage I-II patients with available paraffin-embedded surgical specimens and clinical information (DFS data only were available for the CUN cohort). The model was applied and the patients were stratified into two risk groups as above (p = 0.041 for DFS and p < 0.001 for OS, log rank test; Figure 3C ). In a Cox multivariate analysis, the PI remained a significant independent risk factor (p = 0.015, HR = 3.25, 95% CI 1.26-8.41 for DFS, and p = 0.021, HR = 2.10, 95% CI 1.12-3.93 for OS) (supplementary material, Table S8 ).
Clinical utility of the prognostic signature
To study the clinical relevance of the proposed molecular model, we analysed the benefit of combining the pathological stage with the molecular prognostic model (PI) in the MDA cohort, employing a bivariable Cox model. As expected, stage alone was a highly significant prognostic factor for both DFS and OS (p < 0.001) (supplementary material, Table S9 ). Moreover, the likelihood ratio significantly increased after addition of the molecular information based on the three proteins (PI) (p < 0.001 for both DFS and OS). This improvement showed that the molecular model complements the stage, enriching the prognostic information.
We next performed a Cox regression analysis to develop a new prognostic model combining stage and the molecular model, which we named the CPI. The formula used to calculate it was CPI = 1.019 × PI + B, where B is a coefficient that changes for each stage (IA, B = 0; IB, B = 0.421; IIA, B = 0.937; IIB, B = 1.063; and IIIA, B = 1.598). The model performance was significantly improved (C-index CPI = 0.71 versus C-index PI = 0.62 for DFS; C-index CPI = 0.70 versus C-index PI = 0.65 for OS). The 5-year survival differences between two groups according to the CPI median were significant for both DFS and OS (p < 0.001) ( Figure 4A) . Moreover, the CPI was independent of clinicopathological parameters (p < 0.001 HR = 2.95, 95% CI 2.13-4.08 for DFS; and p < 0.001, HR = 2.56, 95% CI 1.88-3.49 for OS) (supplementary material, Table S10 ). We further extended this combined model to the CIBERES-CUN cohort to validate the prognostic value of the CPI. As expected, the OS risk stratification , and SLC2A1 (E and F). BRCA1 was found predominantly in the nucleus; QKI was located in both the nuclear and cytoplasmic compartments; and SLC2A1 was located in the cell membrane and cytoplasm. Scale bar: 60 μm.
was significantly increased when the PI was combined with stage (p < 0.001, Figure 4B ; C-index CPI = 0.70 versus C-index PI = 0.67). We additionally studied recurrence in the CUN independent cohort. Noticeably, the outcome differences between low and high CPI segmentation were also significant (p = 0.001, Figure 4B ; C-index CPI = 0.71 versus C-index PI = 0.59). After multivariate analysis, CPI was an independent risk factor for OS (p < 0.001, HR = 2.36, 95% CI 1.58-3.51; supplementary material, Table S11 ) and DFS (p = 0.011, HR = 2.17, 95% CI 1.20-3.92; supplementary material, Table S11 ).
Finally, we analysed the potential ability of our prognostic model to provide more than just prognostic information. We interrogated our data in order to determine whether the model was able to predict which stage I-IIA patients would benefit from adjuvant therapy following surgical resection. We stratified the MDA cohort by the CPI median into two groups (high and low). Then, we analysed the clinical outcome in both groups according to postsurgical treatment. This analysis revealed that patients with a high CPI who received platinum-based adjuvant chemotherapy had better survival (p = 0.013 for DFS and p = 0.009 for OS; Figure 4C ), whereas no differences were observed in patients with a low CPI (p = 0.657 for DFS and p = 0.153 for OS). These findings suggest that the CPI may be useful for selecting stage I-IIA patients with poor prognosis who may benefit from adjuvant therapy.
To assess the utility of the signature in stage I patients, we conducted a subanalysis in this subgroup, and demonstrated that the classifier was able to separate the patients according their risk of recurrence and/or death in both the test and training cohorts (supplementary material, Figure S13 ). Moreover, in this subgroup of stage I patients, we observed a benefit in high-CPI patients who received adjuvant chemotherapy (p = 0.044 for DFS and p = 0.011 for OS), whereas no benefit was observed in the low-CPI patients (p = 0.440 for DFS and p = 0.180 for OS) (supplementary material, Figure S14 ).
Discussion
Optimal lung cancer management in surgically resected patients requires the refinement of individualized treatment decisions. The development of biological discrimination criteria with which to select early-stage patients on the basis of their risk of relapse will help to determine the best treatment options. In this study, we have identified and validated a protein-based signature as a reliable prognostic tool for the classification of early-stage lung (1) it is based on the expression of proteins, which are the functionally relevant end-products of the gene expression process; (2) the technology uses simple and affordable immunodetection techniques on FFPE tissue samples; (3) multiple quality controls have been applied to test the specificity of the commercially available antibodies used; (4) stringent and robust statistical methods guarantee the validity of the results; (5) concordant results are found in different independent cohorts of patients; (6) the clinical utility of our model for risk stratification in early-stage ADC patients and the subsequent added value of the signature with respect to the staging information provided by the TNM staging system are clearly shown; and (7) the potential clinical utility of our signature for selecting patients who could benefit from platinum-based adjuvant chemotherapy.
Through a series of filters and strict selection criteria, we chose a group of genes that have been previously associated with lung cancer prognosis alone or in combination with others [8, 9, 20, 22, 25, [32] [33] [34] [35] [36] [37] [38] [39] [40] [41] . After applying a thorough method based on Cox regression, we have developed a robust prognostic algorithm for early-stage lung ADC prognostication. Several published signatures for ADC comprise dozens to hundreds of genes. In contrast, our parsimonious classifier is composed of just three proteins. The model stratifies the patients into two risk groups according to recurrence or death, and clearly provides additional information to that provided by the staging prognostic tool. Moreover, we have also developed a combined prognostic index (CPI), including the molecular PI and the pathological stage. Our CPI is able to stratify the risk of recurrence or death better than stage or the PI separately. A similar analysis was conducted by Grinberg et al, combining a four-protein model and clinicopathological data (stage, age, and performance status). In that study, the protein markers failed to outperform the clinical parameters [42] , although the addition of the protein markers to the clinicopathological features increased the prognostic power of the signature. Using a different statistical approach, i.e. bivariable Cox analysis, we were able to demonstrate that our CPI not only improves the performance of the PI 428 E Martínez-Terroba et al (higher C-indexes) but also complements the prognostic information provided by the stage (better likelihood ratio). Several studies have proposed the use of mRNA signatures to characterize the prognosis in lung ADC [43] . Two of the most developed ones were proposed by Study of the predictive value of the prognostic signature in the MDA cohort (stage I-IIA patients). Kaplan-Meier curves for high-CPI and low-CPI groups comparing differences between patients treated or not treated with adjuvant chemotherapy for DFS (top panels) and OS (lower panels). Patients were stratified into two groups according to the median of the CPI. Differences between groups were evaluated with the log rank test.
allows the assessment of protein expression in a specific subcellular compartment. This issue has been proved to be relevant, as two (SLC2A1 and QKI) of the three proteins included in the signature are present in two different subcellular locations. In the case of SLC2A1 (also known as GLUT1), which is a glucose transporter that is located in the cytoplasm and the membrane of the cells, only membranous expression was relevant for prediction of the prognosis of ADC patients. The expression and
E Martínez-Terroba et al
We have observed that both expression levels are related to prognosis but in different ways, with high levels of nuclear QKI being associated with good prognosis, and high levels of cytoplasmic QKI being associated with worse outcome. We hypothesize that the opposite prognostic roles that we have observed for the nuclear and the cytoplasmic levels of QKI in lung tumours could be related to the presence of different isoforms recognized by the antibody in both subcellular compartments [45] . BRCA1 is a nuclear protein involved in essential cellular processes, including DNA repair and cell cycle regulation. It has been described as a tumour suppressor in different malignant neoplasias [46] . However, in lung cancer, several studies have shown that BRCA1 is strongly associated with poor survival and sensitivity to chemotherapy in NSCLC patients [47] .
In the emerging era of personalized medicine, well-established immunohistochemical assays might be the optimal method for introducing molecular markers into routine clinical practice [48, 49] . Nonetheless, a potential caveat of our study is the interpretation of the immunohistochemical staining. The semiquantitative method used here was performed by two experienced readers independently, and this makes it significantly time-consuming. Quantitative automated image analysis tools could solve this problem, while also reducing interobserver variability between facilities, which is an important issue in implementing these signatures in routine clinical practice.
The benefit of adjuvant treatment in stage I-IIA patients remains controversial. Some PCR-based predictive signatures have been proposed to date [7, 50] , but, so far, none has been incorporated into clinical practice. We demonstrated that our classifier is able to discriminate those stage I-IIA patients at high risk of recurrence and/or death who may benefit from platinum-based adjuvant therapy. Moreover, the signature also identifies those good-prognosis patients who could be spared adjuvant treatment. Further validations in independent cohorts and prospective studies are required to fully confirm these findings.
In summary, our study identifies and validates a three protein-based signature for early-stage lung ADC patients. Moreover, the CPI, a combination of both molecular and clinical criteria, shows potential clinical utility and great feasibility to be translated to clinical practice. Finally, the use of the protein-based prognostic signature proposed in this study could help clinicians to select the optimal treatment for early-stage patients, improving their clinical outcomes.
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